Target
circulating tumor DNA (ctDNA)
6 abstracts
Abstract
Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma.Org: Department of gastroenterology and gastrointestinal oncology, National Cancer Center Hospital East, Kashiwa, Japan, Division of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan, Natera, Inc., Austin, TX, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.Org: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
First report of tumor-informed circulating tumor DNA in fibrolamellar carcinoma in adolescents and young adults: 51 patients.Org: Columbia University - Mailman School of Public Health, FibroFighters Foundation, Rush University Medical Center, University of Zürich, St George Hospital,
Abstract
High rates of detection of metastatic/recurrent colorectal cancer on clinical imaging at the time of molecular residual disease testing following operative management.Org: University of Wisconsin Carbone Cancer Center, Madison, WI,
Abstract
Circulating tumor DNA detection as a prognostic tool in patients with localized colon cancer: A systematic review and meta-analysis.Org: University of Louisville Hospital, University of Louisville, James Graham Brown Cancer Center,
Abstract
Failure rates of mutation-based ctDNA assays in lung cancer treatment monitoring.Org: Johns Hopkins University Bloomberg School of Public Health, DELFI Diagnostics, Delfi Diagnostics, Inc., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine,